Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.91 |
| ▸ | POLB | P06746 | 5/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.91 |
| ▸ | APEX1 | P27695 | 3/20 | 0.91 |
| ▸ | RECQL | P46063 | 2/20 | 0.91 |
| ▸ | P4HB | P07237 | 7/20 | 0.89 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | ALPL | P05186 | 2/20 | 0.79 |
| ▸ | ALPI | P09923 | 2/20 | 0.79 |
| ▸ | ALPG | P10696 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.78 |
| ▸ | CA12 | O43570 | 2/20 | 0.78 |
| ▸ | CA2 | P00918 | 2/20 | 0.78 |
| ▸ | CA4 | P22748 | 2/20 | 0.78 |
| ▸ | CA7 | P43166 | 2/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
| ▸ | NQO2 | P16083 | 1/20 | 0.75 |
| ▸ | XDH | P47989 | 2/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38650627 | 1.00 | GAA (0.91) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL30870432 | 1.00 | GAA (0.91) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL26679507 | 1.00 | GAA (0.91) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL29504121 | 1.00 | GAA (0.91) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL30637484 | 1.00 | GAA (0.91) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL29208522 | 0.97 | P4HB (0.87) | GAAPOLBKDM4EAPEX1RECQL | |
| SCHEMBL31004910 | 0.96 | P4HB (0.88) | GAAPOLBKDM4EAPEX1RECQL | |
| Camelliaside A SCHEMBL30637486 | 0.96 | P4HB (0.83) | GAAPOLBKDM4EAPEX1RECQL | |
| Camelliaside A SCHEMBL13328501 | 0.96 | P4HB (0.83) | GAAPOLBKDM4EAPEX1RECQL | |
| Camelliaside A SCHEMBL29882538 | 0.96 | P4HB (0.83) | GAAPOLBKDM4EAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-119857107-A | Application of kaempferol-3-O-neohesperidin in preparation of medicines for preventing and treating myocardial injury | 天津中医药大学 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | GAA 805/4885POLB 1095/4885KDM4E 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.